Lista de obras -

Accurate Prediction of Response to Interferon-based Therapy in Egyptian Patients with Chronic Hepatitis C Using Machine-learning Approaches

scholarly article published August 2012

Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.

artículo científico publicado en 2017

Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma

artículo científico publicado en 2017

Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.

artículo científico publicado en 2013

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.

artículo científico publicado en 2018

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

artículo científico publicado en 2017

Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.

artículo científico publicado en 2007

Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment

artículo científico publicado en 2013

High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial

artículo científico publicado en 2017

High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

scientific article published on 23 June 2019

How to optimize HCV therapy in genotype 4 patients.

artículo científico

Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4

artículo científico publicado en 2013

IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.

artículo científico publicado en 2015

ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.

artículo científico publicado en 2017

Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients.

artículo científico publicado en 2017

Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.

artículo científico publicado en 2014

Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

artículo científico publicado en 2009

Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.

artículo científico publicado en 2015

Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection

artículo científico publicado en 2013

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

artículo científico publicado en 2012

Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup.

artículo científico publicado en 2012

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.

artículo científico

Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.

artículo científico publicado en 2017

Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques

artículo científico publicado en 2016

Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients

artículo científico publicado en 2016

Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.

artículo científico publicado en 2016

Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.

artículo científico publicado en 2017

Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.

artículo científico publicado en 2016

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.

artículo científico publicado en 2011

Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.

artículo científico publicado en 2017

The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.

artículo científico publicado en 2018

The future for the treatment of genotype 4 chronic hepatitis C.

artículo científico

Value of α-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection.

artículo científico publicado en 2010

Lista de obras de

Accurate Prediction of Response to Interferon-based Therapy in Egyptian Patients with Chronic Hepatitis C Using Machine-learning Approaches

Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon.

Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma

Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response.

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens.

Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.

Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C.

Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment

High Dose of Silymarin in Patients with Decompensated Liver Disease: A Randomized Controlled Trial

High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

How to optimize HCV therapy in genotype 4 patients.

Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4

IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.

ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.

Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients.

Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.

Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.

Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study.

Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection

NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients

Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup.

Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues.

Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.

Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques

Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients

Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.

Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.

Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.

Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.

The adverse effects of interferon-free regimens in 149 816 chronic hepatitis C treated Egyptian patients.

The future for the treatment of genotype 4 chronic hepatitis C.

Value of α-smooth muscle actin and glial fibrillary acidic protein in predicting early hepatic fibrosis in chronic hepatitis C virus infection.